Namwiwat Medical vs Business Alignment: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Namwiwat Medical (NAM.BK)

Q3 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

August 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Latest21 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Business Alignment Public Company Limited (BIZ.BK)

Q3 202623 Jul – 8 Oct 2026

▲4

BIZ profit jumps, BIZGENES launch and Forbes nod lift growth story

Q2 profit surge and double-digit growth target BIZ's second-quarter 2026 net profit jumped 87.75% to 85.18 million baht and revenue rose 29.51%, with management keeping its double-digit full-year growth target. Strong earnings and a 1.259 billion baht backlog give investors confidence in future revenue, pushing the stock up.
The profit surge and maintained growth target are the core new financial results driving the stock.
BIZGENES launch opens new longevity market BIZ launched BIZGENES, a Thai DNA testing and precision health brand, to capture the healthy-longevity trend. It is expanding marketing and service channels across hospitals, clinics and consumers. This new business line adds future revenue and supports the growth story, lifting the stock.
The BIZGENES brand launch is a new growth driver that expands BIZ's addressable market.
Forbes Asia recognition boosts credibility BIZ was named to Forbes Asia's Best Under A Billion list for 2026, one of 18 Thai companies selected. Such recognition raises the company's profile with investors and can attract new buyers, supporting demand for the shares.
The Forbes award is a new external validation that can improve investor sentiment and visibility.
Strong governance score and new project bidding BIZ scored a perfect 100 on the 2026 AGM Checklist for the third straight year, signaling good governance. It is also bidding for government and medical school projects and aims for 200 million baht in recurring after-sales revenue within 2-3 years, supporting future earnings.
The governance score and bidding activity are new positive factors that reinforce the growth outlook.

August 202623 Jul – 8 Oct 2026

▲4

BIZ profit jumps, BIZGENES launch and Forbes nod lift growth story

Q2 profit surge and double-digit growth target BIZ's second-quarter 2026 net profit jumped 87.75% to 85.18 million baht and revenue rose 29.51%, with management keeping its double-digit full-year growth target. Strong earnings and a 1.259 billion baht backlog give investors confidence in future revenue, pushing the stock up.
The profit surge and maintained growth target are the core new financial results driving the stock.
BIZGENES launch opens new longevity market BIZ launched BIZGENES, a Thai DNA testing and precision health brand, to capture the healthy-longevity trend. It is expanding marketing and service channels across hospitals, clinics and consumers. This new business line adds future revenue and supports the growth story, lifting the stock.
The BIZGENES brand launch is a new growth driver that expands BIZ's addressable market.
Forbes Asia recognition boosts credibility BIZ was named to Forbes Asia's Best Under A Billion list for 2026, one of 18 Thai companies selected. Such recognition raises the company's profile with investors and can attract new buyers, supporting demand for the shares.
The Forbes award is a new external validation that can improve investor sentiment and visibility.
Strong governance score and new project bidding BIZ scored a perfect 100 on the 2026 AGM Checklist for the third straight year, signaling good governance. It is also bidding for government and medical school projects and aims for 200 million baht in recurring after-sales revenue within 2-3 years, supporting future earnings.
The governance score and bidding activity are new positive factors that reinforce the growth outlook.

Latest23 Jul – 8 Oct 2026

▲4

BIZ profit jumps, BIZGENES launch and Forbes nod lift growth story

Q2 profit surge and double-digit growth target BIZ's second-quarter 2026 net profit jumped 87.75% to 85.18 million baht and revenue rose 29.51%, with management keeping its double-digit full-year growth target. Strong earnings and a 1.259 billion baht backlog give investors confidence in future revenue, pushing the stock up.
The profit surge and maintained growth target are the core new financial results driving the stock.
BIZGENES launch opens new longevity market BIZ launched BIZGENES, a Thai DNA testing and precision health brand, to capture the healthy-longevity trend. It is expanding marketing and service channels across hospitals, clinics and consumers. This new business line adds future revenue and supports the growth story, lifting the stock.
The BIZGENES brand launch is a new growth driver that expands BIZ's addressable market.
Forbes Asia recognition boosts credibility BIZ was named to Forbes Asia's Best Under A Billion list for 2026, one of 18 Thai companies selected. Such recognition raises the company's profile with investors and can attract new buyers, supporting demand for the shares.
The Forbes award is a new external validation that can improve investor sentiment and visibility.
Strong governance score and new project bidding BIZ scored a perfect 100 on the 2026 AGM Checklist for the third straight year, signaling good governance. It is also bidding for government and medical school projects and aims for 200 million baht in recurring after-sales revenue within 2-3 years, supporting future earnings.
The governance score and bidding activity are new positive factors that reinforce the growth outlook.